Comparison of BRCA Versus non-BRCA Germline Mutations and Associated Somatic Mutation Profiles in Patients With Unselected Breast Cancer
Affiliations
- PMID: 32091409
- DOI: 10.18632/aging.102783
Abstract
The data on the phenotypes associated with some rare germline mutations in Chinese breast cancer patients are limited. The difference in somatic mutation profiles in breast cancer patients with germline BRCA and non-BRCA mutations remains unexplored. We interrogated the germline and somatic mutational profile of 524 Chinese breast cancer patients with various stages unselected for predisposing factors using a panel consisting of 520 cancer-related genes including 62 cancer susceptibility genes. We divided the patients into three groups according to germline mutations: Germline-BRCA1/2, Germline-others (non-BRCA) and Others (non-carriers). A total of 58 patients (11.1%) carried 76 likely pathogenic or pathogenic (LP/P) germline variants in 15 cancer predisposition genes. Germline BRCA1/2 mutations were detected from 29 (5.53%) patients; with 11 (2.10%) BRCA1 carriers and 18 (3.44%) BRCA2 carriers. In addition, LP/P germline mutations were detected in other genes including MUTYH (n=4), PALB2 (n=4), ATM (n=3), BRIP1 (n=3), CDH1 (n=3), RAD51C (n=3), CHEK2 (n=2), FANCA (n=2), PMS2 (n=2), TP53 (n=2), FANCI (n=1), FANCL (n=1) and PTEN (n=1). At least one variant of uncertain significance (VUS) was identified in 490 (93.5%) patients. Young age (P=0.011), premenopausal status (P=0.013), and breast/ovarian cancer family history (P=0.001) were correlated with germline mutations. Germline-BRCA1/2 group was detected with more missense (P=0.02) and less copy-number amplification (P=0.04) than Germline-others group. Meanwhile, Germline-others group and Others group are very similar (P>0.05). The mutation rates of AKT1, CCND1, FGFR1, and PIK3CA were different among the three groups. By investigating all breast and ovarian cancer-related genes listed in the US genetic guidelines, we identified 15 cancer susceptibility genes frequently mutated in the germline of our population and must be included in cancer predisposition screening. Our study contributed a better understanding of the tumor characteristics of patients with LP/P germline mutations.
Keywords: BRCA; breast cancer; germline mutations; non-BRCA; somatic mutations.
Similar articles
- Germline and Somatic Mutations of Multi-Gene Panel in Chinese Patients With Epithelial Ovarian Cancer: A Prospective Cohort StudyW Li et al. J Ovarian Res 12 (1), 80. PMID 31472684.This is the first report of multi-gene panel testing for germline and somatic mutations among Chinese EOC patients, which revealed a broader deleterious variants than onl …
- Pathogenic and Likely Pathogenic Variants in PALB2, CHEK2, and Other Known Breast Cancer Susceptibility Genes Among 1054 BRCA-negative Hispanics With Breast CancerJN Weitzel et al. Cancer 125 (16), 2829-2836. PMID 31206626.Of 1054 BRCA-negative, high-risk Hispanic women, 4.5% carried a PV in a cancer susceptibility gene, increasing understanding of hereditary BC in this population. Recurren …
- Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 Mutations in High-Risk Finnish BRCA1/2-founder Mutation-Negative Breast and/or Ovarian Cancer IndividualsKM Kuusisto et al. Breast Cancer Res 13 (1), R20. PMID 21356067.In this study, mutations in previously known breast cancer susceptibility genes can explain 13.4% of the analyzed high-risk BRCA1/2-negative HBOC individuals. CHEK2 mutat …
- Recommendations for Preventive Care for Women With Rare Genetic Cause of Breast and Ovarian CancerL Foretová et al. Klin Onkol 32 (Supplementum2), 6-13. PMID 31409076. - ReviewAn inherited predisposition to breast cancer underlies 5-10% of breast tumors. High-risk BRCA1 and BRCA2 genes result in an 85% lifetime risk of breast cancer and a 20-60 …
- Selecting Patients With Ovarian Cancer for Germline BRCA Mutation Testing: Findings From Guidelines and a Systematic Literature ReviewDM Eccles et al. Adv Ther 33 (2), 129-50. PMID 26809252. - ReviewWith the availability of BRCA mutation-targeted therapies, identification of patients with OC with germline BRCA mutations has potential therapeutic consequences. For ide …
No hay comentarios:
Publicar un comentario